- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
A look back at the year's worth of Adam Feuerstein's biotech tweets.
The thwarted Medivation bidder lifts its full-year earnings estimates and announces a share buyback program.
A day after winning approval for a cancer drug, Merck posts earnings and sales that beat consensus estimates.